Madrigal Pharmaceuticals, Inc.
MDGL
$307.78
-$13.32-4.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 302.29% | 346.87% | 328.76% | 216.10% | 124.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.19% | 79.24% | 64.88% | 44.50% | 29.61% |
| Operating Income | -30.85% | -57.21% | -60.45% | -44.50% | -29.61% |
| Income Before Tax | -24.69% | -49.33% | -54.78% | -41.16% | -26.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.69% | -49.33% | -54.78% | -41.16% | -26.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.69% | -49.33% | -54.78% | -41.16% | -26.50% |
| EBIT | -30.85% | -57.21% | -60.45% | -44.50% | -29.61% |
| EBITDA | -30.74% | -57.19% | -60.48% | -44.54% | -29.64% |
| EPS Basic | -10.89% | -30.31% | -36.76% | -27.58% | -15.71% |
| Normalized Basic EPS | -10.89% | -30.31% | -36.76% | -27.58% | -15.71% |
| EPS Diluted | -10.89% | -30.31% | -36.76% | -27.58% | -15.71% |
| Normalized Diluted EPS | -10.89% | -30.31% | -36.76% | -27.58% | -15.71% |
| Average Basic Shares Outstanding | 13.84% | 14.81% | 12.42% | 9.93% | 9.03% |
| Average Diluted Shares Outstanding | 13.84% | 14.81% | 12.42% | 9.93% | 9.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |